Primary Site >> Pancreatic Cancer
Gene >> KRAS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Activation of the c-K-ras oncogene in a human pancreas carcinoma. PMID: 3855240 |
Ref: Visualization of c-Ki-ras-2 oncogene sequences in human pancreas, a chemically induced transplantable carcinoma, and carcinomas of pancreas by in situ hybridization. PMID: 3681029 Ref: Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation. PMID: 3778442 |
Ref: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. PMID: 2453289 Ref: Oncogene expression in endocrine pancreatic tumors. PMID: 2904191 Ref: Amplification of c-Ki-ras-2 oncogene sequences in human carcinoma of pancreas. PMID: 3280705 |
Ref: Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. PMID: 2507485 |
Ref: Mutational activation of the c-K-ras gene in human pancreatic carcinoma. PMID: 1976394 Ref: Expression of c-myc, c-raf-1, and c-Ki-ras in azaserine-induced pancreatic carcinomas and growing pancreas in rats. PMID: 2278633 |
Ref: [Point mutation of c-k-ras oncogene at codon 12 in mucin-producing cystic tumor of the pancreas]. PMID: 1662731 Ref: Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. PMID: 1663781 Ref: Analysis of ras gene mutations in gastrointestinal cancers. PMID: 1686883 Ref: Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. PMID: 1773797 Ref: Activation of c-K-ras is frequent in pancreatic carcinomas of Syrian hamsters, but is absent in pancreatic tumors of rats. PMID: 1860169 Ref: [Detection of point mutation of Kirsten ras oncogene in pancreatic carcinoma by polymerase chain reaction]. PMID: 1870574 Ref: c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. PMID: 1955373 |
Ref: Recent results in animal models of pancreatic carcinoma: histogenesis of tumors. PMID: 1340063 Ref: [Expression of c-myc and c-ki-ras oncogene in human pancreatic carcinoma]. PMID: 1396043 Ref: Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. PMID: 1444240 |
Ref: Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. PMID: 7902444 Ref: Neoplastic transformation of propagable cultured rat pancreatic duct epithelial cells by azaserine and streptozotocin. PMID: 8099312 Ref: Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. PMID: 8249918 Ref: [Sensitive detection of K-ras oncogene codon 12 mutations by nested PCR using mismatched primers and selective digestion of non-mutated PCR fragments with restriction enzyme]. PMID: 8254964 Ref: The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas. PMID: 8283077 Ref: Inhibition of human pancreatic cancer cell (MIA PaCa-2) growth by cholera toxin and 8-chloro-cAMP in vitro. PMID: 8381655 Ref: Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. PMID: 8407563 Ref: p53 and K-RAS alterations in pancreatic epithelial cell lesions. PMID: 8426738 Ref: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. PMID: 8495407 Ref: Possible association of nm23 gene-expression and ki-ras point mutations with metastatic potential in human pancreatic cancer-derived cell-lines. PMID: 21573412 |
Ref: [Point mutation at codon 12 of c-Ki-ras oncogene in human pancreatic neoplasms and normal human pancreas tissue]. PMID: 7805165 Ref: Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. PMID: 7809022 Ref: Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing. PMID: 7876379 Ref: Ki-ras mutations in pancreatic secretions and aspirates from two patients without pancreatic cancer. PMID: 7932811 Ref: [Lesions of the pancreatic duct epithelium and histogenesis of exocrine pancreatic carcinomas]. PMID: 7947629 Ref: [Analysis of Ki-ras in pancreatic fluid aspirate. A new diagnostic possibility in investigation of pancreatic cancer]. PMID: 7974428 Ref: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. PMID: 8012983 Ref: Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. PMID: 8026879 Ref: Only wild-type c-Ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas. PMID: 8031464 Ref: Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. PMID: 8063617 Ref: [Point mutation of K-ras gene in pancreatic carcinoma]. PMID: 8069725 Ref: Soluble normal and mutated DNA sequences from single-copy genes in human blood. PMID: 8118388 Ref: Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. PMID: 8156485 Ref: Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. PMID: 8157353 Ref: Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. PMID: 8178941 |
Ref: Peritoneal exfoliative cytology and Ki-ras mutational analysis in patients with pancreatic adenocarcinoma. PMID: 7497464 Ref: Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. PMID: 7559078 Ref: Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. PMID: 7598300 Ref: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. PMID: 7641198 Ref: [Mutation of the K-ras oncogene in pancreatic carcinoma, and application of its detection in pancreatic juice to diagnose pancreatic carcinoma]. PMID: 7699881 Ref: Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. PMID: 7730480 Ref: [Ki-ras mutation as a molecular tumor marker for carcinoma of the pancreas]. PMID: 7781522 Ref: [Ki-ras mutation--a specific and sensitive tumor marker for carcinoma of the pancreas?]. PMID: 7781524 Ref: Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. PMID: 7797131 Ref: Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin. PMID: 7870083 Ref: Mixed pleomorphic-osteoclast-like tumor of the pancreas. Light microscopical, immunohistochemical, and molecular biological studies. PMID: 8530833 Ref: Detection of point mutations in K-ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures. PMID: 8708392 Ref: [Reversal of malignant cell phenotype of human pancreatic adenocarcinoma cell line by recombinant retroviral vector expressing antisense Ki-ras]. PMID: 8745475 Ref: Detection of c-Ki-ras mutations in bile samples from patients with pancreatic and biliary cancers. PMID: 16696030 Ref: Effects of antisense oligonucleotides targeting k-ras expression in pancreatic-cancer cell-lines. PMID: 21556647 |
Ref: Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. PMID: 8536860 Ref: Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. PMID: 8536861 Ref: ERCP meets C-K-ras: towards an improved diagnosis of pancreatic cancer. PMID: 8536877 Ref: p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. PMID: 8569192 Ref: Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. PMID: 8602613 Ref: Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. PMID: 8609057 Ref: Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. PMID: 8613066 Ref: High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. PMID: 8625455 Ref: Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutation. PMID: 8641983 Ref: [Sensitivity and specificity of tumor markers in cancer diagnosis]. PMID: 8691613 Ref: Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. PMID: 8726178 Ref: K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. PMID: 8740403 Ref: Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. PMID: 8759672 Ref: An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. PMID: 8760597 Ref: Clinical significance of K-ras oncogene activation in ampullary neoplasms. PMID: 8763258 Ref: Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma. PMID: 8797884 Ref: Double cancer in a 74-year-old woman: a case report with genetic findings. PMID: 8804161 Ref: [Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor]. PMID: 8886038 Ref: Signal transduction as target of gene therapy. PMID: 8893335 Ref: Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. PMID: 8927612 Ref: Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. PMID: 8968863 Ref: Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. PMID: 8971180 Ref: C-Ki-ras mutations in peripheral blood of pancreatic cancer patients: a marker for early tumor metastasis. PMID: 12118546 |
Ref: Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. PMID: 9001550 Ref: KRAS oncogene mutations suggest a common histogenetic origin for pleomorphic giant cell tumor of the pancreas, osteoclastoma of the pancreas, and pancreatic duct adenocarcinoma. PMID: 9013836 Ref: Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. PMID: 9041151 Ref: Adenosquamous carcinoma arising in a mucinous cystadenoma of the pancreas. PMID: 9047255 Ref: Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. PMID: 9070877 Ref: Ki-ras mutations in exocrine pancreatic cancer: association with clinico-pathological characteristics and with tobacco and alcohol consumption. PANK-ras I Project Investigators. PMID: 9096646 Ref: Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. PMID: 9100777 Ref: Sclerosing pancreatitis showing rapidly progressive changes with recurrent mass formation. PMID: 9127178 Ref: Tumor-suppressive pathways in pancreatic carcinoma. PMID: 9135016 Ref: Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. PMID: 9137410 Ref: p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. PMID: 9187111 Ref: Activation of Raf-1 in human pancreatic adenocarcinoma. PMID: 9202670 Ref: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. PMID: 9209954 Ref: Molecular diagnosis of pancreas carcinoma. PMID: 9219065 Ref: [Molecular diagnosis of pancreatic cancer]. PMID: 9276865 Ref: [Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others]. PMID: 9276872 Ref: The incidence of port-site metastases might be reduced. PMID: 9294269 Ref: Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. PMID: 9322121 Ref: Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. PMID: 9351717 Ref: Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. PMID: 9364215 Ref: The molecular genetics of pancreatic cancer. PMID: 9364657 Ref: Differential oligonucleotide activity in cell culture versus mouse models. PMID: 9383573 Ref: Increased telomerase activities in human pancreatic duct adenocarcinomas. PMID: 9414659 Ref: Molecular advances in pancreatic cancer. PMID: 9438601 Ref: [Instrumental diagnosis for therapy decision making--what is possible and desirable, what is indispensible and what is superfluous in tumors of the pancreas?]. PMID: 9574160 Ref: [Detection of the Ki-ras mutation as a specific and sensitive marker of pancreatic carcinoma]. PMID: 9601883 Ref: [Inhibition of cell growth and target gene expression of human pancreatic carcinoma cells by modified antisense oligodeoxynucleotide]. PMID: 10072855 Ref: [The inhibitory effect of combined treatment of TNF alpha and antisense oligodeoxynucleotides on the growth of human pancreatic carcinoma cell line cells]. PMID: 10374336 Ref: Analysis of K-ras gene mutations in human pancreatic cancer cell lines and in bile samples from patients with pancreatic and biliary cancers. PMID: 21590256 |
Ref: K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. PMID: 9428484 Ref: Role of growth factors in pancreatic cancer. PMID: 9443985 Ref: Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. PMID: 9459160 Ref: Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. PMID: 9472115 Ref: Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-ras mutation. PMID: 9477096 Ref: Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. PMID: 9496909 Ref: Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. PMID: 9529487 Ref: Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. PMID: 9538122 Ref: Pancreatic cancer: medical aspects. PMID: 9548678 Ref: K-ras mutations at codon 12 are rare events in chronic pancreatitis. PMID: 9586823 Ref: Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy. PMID: 9587115 Ref: Analysis of K-ras oncogene mutation directly applied to atypical cell clusters on cytologic smear slides of bile and pancreatic juice. PMID: 9589462 Ref: Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. PMID: 9620027 Ref: Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. PMID: 9626054 Ref: K-ras mutation in focal proliferative lesions of human pancreas. PMID: 9641496 Ref: Molecular pattern of ductal pancreatic cancer. PMID: 9641882 Ref: Detection of Ki-ras and p53 gene mutations in tissue and pancreatic juice from pancreatic adenocarcinomas. PMID: 9658319 Ref: K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. PMID: 9671070 Ref: Clinical application of K-ras oncogene mutations in pancreatic carcinoma: detection of micrometastases. PMID: 9671955 Ref: Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. PMID: 9713360 Ref: [Adenocarcinoma of the pancreas. General characteristics]. PMID: 9767968 Ref: K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. PMID: 9777987 Ref: K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits. PMID: 9799749 Ref: Restriction digest PCR (RD-PCR) for the analysis of gene mutations. Application to Ki-ras. PMID: 9806467 Ref: Cholecystokinin receptors in human pancreatic cancer cell lines. PMID: 9849431 Ref: Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. PMID: 9875139 Ref: Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. PMID: 9878544 Ref: Analysis of K-ras gene mutations in rare pancreatic and ampullary tumours. PMID: 9895049 Ref: Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival. PMID: 10076772 Ref: Learning from case reports: diagnostic issues in an epidemiologic study of pancreatic cancer. PMID: 10086813 Ref: [Detection of hepatic micrometastasis in ductal pancreatic carcinoma by K-ras mutation analysis and determination of clinical relevance]. PMID: 14518210 |
Ref: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. PMID: 9918209 Ref: Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. PMID: 9935156 Ref: K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. PMID: 10080602 Ref: Characterization of six cell lines established from human pancreatic adenocarcinomas. PMID: 10091760 Ref: K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination. PMID: 10189896 Ref: Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. PMID: 10228857 Ref: K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. PMID: 10328172 Ref: Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. PMID: 10348828 Ref: Malignant fibrous histiocytoma of the pancreas: a case report with genetic analysis. PMID: 10357405 Ref: Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. PMID: 10373591 Ref: The role of p21ras in pancreatic neoplasia and chronic pancreatitis. PMID: 10374765 Ref: Enrichment polymerase chain reaction for the detection of Ki-ras mutations: relevance of Taq polymerase error rate, initial DNA copy number, and reaction conditions on the emergence of false-positive mutant bands. PMID: 10394959 Ref: Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. PMID: 10402237 Ref: Ki-ras oncogene mutations in chronic pancreatitis: which discriminating ability for malignant potential? PMID: 10415866 Ref: In vitro pancreatic carcinogenesis. PMID: 10436783 Ref: Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool. PMID: 10436800 Ref: Analysis of K-ras mutations in pancreatic tissue after fine needle aspirates. PMID: 10470178 Ref: Detection of codon 12 mutation in the K-ras oncogene in pancreatic tumors. PMID: 10488596 Ref: Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases. PMID: 10522044 Ref: Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. PMID: 10522720 Ref: Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum. PMID: 10548352 Ref: Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. PMID: 10592048 Ref: Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. PMID: 10609819 Ref: Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. PMID: 10624710 Ref: Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. PMID: 10656099 Ref: Detection of extrapancreatic nerve plexus invasion of pancreatic adenocarcinoma. Cytokeratin 19 staining and K-ras mutation. PMID: 10732292 Ref: [K-ras mutation in pancreatic juice from patients with pancreatic carcinoma]. PMID: 11798705 Ref: [The establishment of a human pancreatic mixed ductal-endocrine carcinoma cell line]. PMID: 11869555 Ref: Molecular genetics and related developments in pancreatic cancer. PMID: 17023981 |
Ref: [General rules for the study of pancreatic cancer by molecular biological aspect]. PMID: 10734643 Ref: Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. PMID: 10750666 Ref: Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. PMID: 10766343 Ref: BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. PMID: 10793087 Ref: Solid and cystic tumor of the pancreas: clinicopathologic and genetic studies of four cases. PMID: 10811026 Ref: Outcome of pancreatic cancer patients based on genetic lymph node staging. PMID: 10811991 Ref: Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1. PMID: 10813711 Ref: Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential. PMID: 10822130 Ref: Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutation. PMID: 10840305 Ref: Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. PMID: 10873061 Ref: [Characteristics of plasma DNA and its application for detection of K-ras gene mutation]. PMID: 10897674 Ref: Ribozyme as an approach for growth suppression of human pancreatic cancer. PMID: 10911615 Ref: K-ras gene mutations and loss of heterozygosity at the p53 gene locus relative to histological characteristics of mucin-producing tumors of the pancreas. PMID: 10923915 Ref: Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer. PMID: 10950039 Ref: Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. PMID: 10950061 Ref: Clinical value of bile for the detection of mutant K-ras from colorectal liver metastases. PMID: 10953312 Ref: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. PMID: 11034087 Ref: Origin of giant cells in osteoclast-like giant cell tumors of the pancreas. PMID: 11070115 Ref: Comparison of K-ras point mutations at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. PMID: 11088049 Ref: K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. PMID: 11097231 Ref: K-ras point mutation in the nerve plexuses around the superior mesenteric artery in resectable adenocarcinoma of the pancreatic head: distribution pattern and related factors. PMID: 11115351 Ref: [Detection of K-ras gene mutations in DNA extracted from the plasma of patients with pancreatic cancer]. PMID: 11832160 |
Ref: Colloid (mucinous noncystic) carcinoma of the pancreas. PMID: 11145249 Ref: Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. PMID: 11169959 Ref: Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. PMID: 11319909 Ref: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. PMID: 11358848 Ref: Enrichment of mutant KRAS alleles in pancreatic juice by subtractive iterative polymerase chain reaction. PMID: 11406644 Ref: Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis. PMID: 11406647 Ref: Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. PMID: 11408925 Ref: Molecular diagnosis of pancreatic cancer. PMID: 11490843 Ref: The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. PMID: 11505392 Ref: A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. PMID: 11526239 Ref: Molecular epidemiology of pancreatic cancer. PMID: 11561602 Ref: Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. PMID: 11668203 Ref: Oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC. PMID: 11668624 Ref: Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. PMID: 11696422 Ref: Does detection of K-ras mutations in pancreatic juice influence clinical decision making? PMID: 11711767 Ref: Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer. PMID: 11711770 Ref: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. PMID: 11751396 |
Ref: DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. PMID: 11719088 Ref: Generalizing molecular results arising from incomplete biological samples: expected bias and unexpected findings. PMID: 11750234 Ref: Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. PMID: 11756230 Ref: Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. PMID: 11861435 Ref: Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. PMID: 11943721 Ref: Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. PMID: 11950919 Ref: Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. PMID: 11979555 Ref: Molecular prognostic markers in pancreatic cancer. PMID: 12021893 Ref: Molecular pathogenesis of pancreatic cancer. PMID: 12063826 Ref: Invasive ductal adenocarcinoma of the remnant pancreatic body 9 years after resection of an intraductal papillary-mucinous carcinoma of the pancreatic head: a case report and comparison of DNA sequence in K-ras gene mutation. PMID: 12072425 Ref: Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. PMID: 12120000 Ref: Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. PMID: 12185592 Ref: Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. PMID: 12189555 Ref: Quantity of mutant K-ras gene in pancreatic secretions for diagnosis of pancreatic carcinoma with different assays: analysis of 100 patients. PMID: 12204431 Ref: Hyperstable U1snRNA complementary to the K-ras transcripts induces cell death in pancreatic cancer cells. PMID: 12373606 Ref: Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial. PMID: 12409332 Ref: [Molecular pathways of pancreatic carcinogenesis]. PMID: 12483152 Ref: Neural invasion in pancreatic carcinoma. PMID: 14607730 |
Ref: K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses. PMID: 12508380 Ref: Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. PMID: 12592366 Ref: The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. PMID: 12649190 Ref: [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma]. PMID: 12654190 Ref: The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. PMID: 12727809 Ref: Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. PMID: 12727811 Ref: Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. PMID: 12802288 Ref: [Molecular factors of pancreatic cancer pathogenesis and prognosis]. PMID: 12878815 Ref: [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer]. PMID: 12892584 Ref: [Molecular diagnosis in pancreatic carcinoma]. PMID: 12931440 Ref: The genetics of pancreatic cancer. PMID: 12946833 Ref: Survival regulation in pancreatic cancer cells by c-Jun. PMID: 12963995 Ref: BRAF and K-ras gene mutations in human pancreatic cancers. PMID: 12969789 Ref: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. PMID: 14507635 Ref: Detection of K-ras gene mutation at codon 12 by pancreatic duct brushing for pancreatic cancer. PMID: 14599992 Ref: Unique GGT --> GTT mutation at K-ras codon 12 in six human pancreatic cancer cell lines from Chinese patients. PMID: 14640107 Ref: Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. PMID: 14681207 Ref: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. PMID: 14706336 Ref: K-ras as a genetic marker in pancreatic cancer. PMID: 14708511 |
Ref: Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. PMID: 14603530 Ref: Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis. PMID: 14718395 Ref: Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1. PMID: 14732924 Ref: Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. PMID: 14742320 Ref: Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer. PMID: 14767540 Ref: Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. PMID: 14767735 Ref: Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. PMID: 14966900 Ref: G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells. PMID: 14992588 Ref: Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. PMID: 15040037 Ref: Pancreatic cancer. PMID: 15051286 Ref: [Recent advances in gene change of pancreatic cancer]. PMID: 15052782 Ref: Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer. PMID: 15112354 Ref: Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic and remetastatic cell lines? PMID: 15113037 Ref: Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding. PMID: 15118760 Ref: Clear cell carcinoma of the pancreas: an adenocarcinoma with unusual phenotype of duct cell origin. PMID: 15127279 Ref: [Alteration of the K-ras and p16/CDKN2 gene in endocrine pancreatic carcinomas]. PMID: 15148814 Ref: Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer. PMID: 15150585 Ref: Clear cell ductal adenocarcinoma of pancreas: a case report and review of the literature. PMID: 15163226 Ref: Ductuloinsular tumors of the pancreas: endocrine tumors with entrapped nonneoplastic ductules. PMID: 15166675 Ref: Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. PMID: 15202051 Ref: Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. PMID: 15452878 Ref: An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer. PMID: 15473338 Ref: [K-ras gene mutation in gallbladder carcinoma]. PMID: 15478297 Ref: LigAmp for sensitive detection of single-nucleotide differences. PMID: 15782177 Ref: (64)Cu-N,N'-Bis(S-benzoyl-thioglycoloyl)diaminopropanoate-KRAS-PNA-d(Cys-Ser-Lys- Cys) PMID: 20641287 Ref: (99m)Tc-N,N'-Bis(S-benzoyl-thioglycoloyl)diamidopropanoyl-KRAS-PNA-d(Cys-Ser-Lys- Cys) PMID: 20641936 |
Ref: Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all. PMID: 498881 Ref: Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. PMID: 15580305 Ref: Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. PMID: 15652748 Ref: Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. PMID: 15655549 Ref: Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette. PMID: 15801000 Ref: Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. PMID: 15832194 Ref: Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. PMID: 15846069 Ref: From pancreatic intraepithelial neoplasia to cancer: a dramatic progression with K-ras status analysis. PMID: 15864214 Ref: Suppression of invasion of a hamster pancreatic cancer cell line by antisense oligonucleotides mutation-matched to K-ras gene. PMID: 15875772 Ref: [Anti-pancreatic cancer immune response induced by K-ras mutated peptide]. PMID: 15890097 Ref: Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all. PMID: 15894260 Ref: [Differential genetic pathway of duct and acinar carcinomas of the pancreas]. PMID: 15918556 Ref: Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. PMID: 15929091 Ref: [Chronic pancreatitis--pancreas cancer: influence of genetic factors]. PMID: 15957615 Ref: In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. PMID: 15958547 Ref: Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma. PMID: 15966189 Ref: Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. PMID: 16046552 Ref: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. PMID: 16049314 Ref: [The expressions of K-ras in human laryngeal squamous cell carcinoma cell lines (Hep-2) and its significance]. PMID: 16075979 Ref: Mutant KRAS in the initiation of pancreatic cancer. PMID: 16169155 Ref: Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. PMID: 16183479 Ref: Synthesis of novel peptide nucleic acid-peptide chimera for non-invasive imaging of cancer. PMID: 16247960 Ref: External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. PMID: 16382049 Ref: [Frequency of K-ras mutation in biliary and pancreatic tumors]. PMID: 16446870 Ref: Ductal pancreatic cancer in humans and mice. PMID: 16869739 |
Ref: Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. PMID: 16257181 Ref: Molecular mechanisms of pancreatic carcinogenesis. PMID: 16367914 Ref: Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. PMID: 16397237 Ref: Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. PMID: 16432256 Ref: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. PMID: 16532023 Ref: Molecular pathogenesis of pancreatic cancer. PMID: 16549325 Ref: Gene therapy developments for pancreatic cancer. PMID: 16549328 Ref: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. PMID: 16598499 Ref: Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. PMID: 16682430 Ref: N-cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-RASG12V and p53V143A in promoting pancreatic cell migration, invasion, and tissue architecture disruption. PMID: 16705170 Ref: Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. PMID: 16707615 Ref: Physiological analysis of oncogenic K-ras. PMID: 16757361 Ref: Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. PMID: 16808798 Ref: Current treatment strategies for pancreatic cancer in the elderly. PMID: 16823993 Ref: Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. PMID: 16931950 Ref: Assay design and optimization of mutant-enriched PCR based method for detection of K-ras gene mutations in pancreatic carcinoma. PMID: 17013530 Ref: Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. PMID: 17114584 Ref: The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. PMID: 18049799 |
Ref: BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. PMID: 17097223 Ref: Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci. PMID: 17203180 Ref: K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. PMID: 17332339 Ref: A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers. PMID: 17349578 Ref: Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. PMID: 17349581 Ref: Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. PMID: 17353198 Ref: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. PMID: 17354229 Ref: [Experiment study on the diagnostic value of bile K-ras gene mutation responsible to the hepatic metastasis of pancreatic cancer]. PMID: 17441357 Ref: K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. PMID: 17489984 Ref: Molecular genetics of pancreatic intraepithelial neoplasia. PMID: 17520196 Ref: Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics. PMID: 17520198 Ref: Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3A-peptide nucleic acid-peptide nanoparticles. PMID: 17611392 Ref: RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. PMID: 17638924 Ref: Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. PMID: 17652141 Ref: The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. PMID: 17671193 Ref: Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. PMID: 17785207 Ref: Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction. PMID: 17879123 Ref: Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PMID: 17982507 Ref: Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass. PMID: 18090159 |
Ref: PIK3CA cancer mutations display gender and tissue specificity patterns. PMID: 18022911 Ref: Pancreatic cancer. PMID: 18039136 Ref: SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. PMID: 18064648 Ref: Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. PMID: 18075308 Ref: Molecular markers of pancreatic cancer: development and clinical relevance. PMID: 18266003 Ref: PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. PMID: 18343945 Ref: Characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms. PMID: 18392710 Ref: Characterization of Kras-mediated pancreatic tumorigenesis in zebrafish. PMID: 18413263 Ref: Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. PMID: 18413752 Ref: Targeting Ras in myeloid leukemias. PMID: 18413813 Ref: [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells]. PMID: 18479599 Ref: Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis. PMID: 18495213 Ref: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. PMID: 18515410 Ref: Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? PMID: 18525343 Ref: [New molecular targets in pancreatic cancer]. PMID: 18541514 Ref: Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. PMID: 18549880 Ref: Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research. PMID: 18589869 Ref: Shining the spotlight on shed KRAS in pancreatic cancer. PMID: 18614859 Ref: Stabilization of beta-catenin induces pancreas tumor formation. PMID: 18725219 Ref: Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides. PMID: 18777594 Ref: SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell. PMID: 18829525 Ref: Rapid screening assay for KRAS mutations by the modified smart amplification process. PMID: 18832461 Ref: Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. PMID: 18836286 Ref: Histopathological features of patients with chronic pancreatitis due to mutations in the PRSS1 gene: evaluation of BRAF and KRAS2 mutations. PMID: 18946221 Ref: Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature. PMID: 19023234 Ref: Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. PMID: 19028876 Ref: [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]. PMID: 19062734 Ref: Precursor lesions of pancreatic cancer. PMID: 20485640 |
Ref: Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. PMID: 18949011 Ref: Identification of a new G-quadruplex motif in the KRAS promoter and design of pyrene-modified G4-decoys with antiproliferative activity in pancreatic cancer cells. PMID: 19099510 Ref: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. PMID: 19109152 Ref: Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. PMID: 19117087 Ref: GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. PMID: 19136624 Ref: Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. PMID: 19147554 Ref: KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. PMID: 19208745 Ref: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. PMID: 19236713 Ref: Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. PMID: 19249398 Ref: Comparison of ras-responsive gene enhancers in pancreatic tumor cells that express either wild-type or mutant K-ras. PMID: 19254697 Ref: Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. PMID: 19270646 Ref: Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. PMID: 19273243 Ref: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. PMID: 19273710 Ref: Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. PMID: 19292977 Ref: let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. PMID: 19323605 Ref: Genetic mutations associated with cigarette smoking in pancreatic cancer. PMID: 19351817 Ref: E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. PMID: 19362090 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. PMID: 19433978 Ref: Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. PMID: 19440048 Ref: Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. PMID: 19440145 Ref: A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses. PMID: 19460940 Ref: K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. PMID: 19509115 Ref: Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. PMID: 19533561 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PMID: 19629168 Ref: Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. PMID: 19671674 Ref: An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. PMID: 19818733 Ref: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. PMID: 19826350 Ref: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PMID: 19826477 Ref: Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. PMID: 19893451 Ref: Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. PMID: 19896096 Ref: Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. PMID: 19951995 Ref: MUTYH exon 7 and 13 mutations associated with colorectal cancer (MAP syndrome) are not commonly associated with sporadic pancreatic cancer. PMID: 20110747 |
Ref: Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. PMID: 19609950 Ref: The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. PMID: 19880966 Ref: Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats. PMID: 19917056 Ref: Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanisms. PMID: 19924021 Ref: Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. PMID: 19931263 Ref: Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. PMID: 19959798 Ref: Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. PMID: 20018721 Ref: Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. PMID: 20071774 Ref: MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. PMID: 20093556 Ref: Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. PMID: 20179210 Ref: Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. PMID: 20182344 Ref: Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. PMID: 20208318 Ref: Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles. PMID: 20232877 Ref: Phenotype and genotype of pancreatic cancer cell lines. PMID: 20418756 Ref: Molecular determinants of the antitumor effects of trichostatin A in pancreatic cancer cells. PMID: 20419833 Ref: PAR-4 as a possible new target for pancreatic cancer therapy. PMID: 20426700 Ref: LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. PMID: 20452353 Ref: Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. PMID: 20518885 Ref: Salirasib in the treatment of pancreatic cancer. PMID: 20528225 Ref: Genomic instability at both the base pair level and the chromosomal level is detectable in earliest PanIN lesions in tissues of chronic pancreatitis. PMID: 20531246 Ref: Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. PMID: 20534740 Ref: K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. PMID: 20542658 Ref: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. PMID: 20610624 Ref: Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors. PMID: 20631070 Ref: Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. PMID: 20701442 Ref: DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. PMID: 20720444 Ref: PTEN loss accelerates KrasG12D-induced pancreatic cancer development. PMID: 20807812 Ref: Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. PMID: 20824720 Ref: Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer. PMID: 20959479 Ref: Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. PMID: 20959520 Ref: TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. PMID: 21044336 Ref: Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. PMID: 21056012 Ref: The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. PMID: 21084261 Ref: Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. PMID: 21159816 Ref: Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. PMID: 21160836 Ref: Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. PMID: 21197450 Ref: Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. PMID: 22966286 Ref: New and potential clinical applications of KRAS as a cancer biomarker. PMID: 23496197 Ref: The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer. PMID: 24281169 Ref: Differences in Molecular Pathologic Characteristics of Pancreatic Adenocarcinoma between Egyptian and Moroccan Patients. PMID: 25598952 |
Ref: Alteration of strain background and a high omega-6 fat diet induces earlier onset of pancreatic neoplasia in EL-Kras transgenic mice. PMID: 20725998 Ref: The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. PMID: 20848283 Ref: Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. PMID: 21199651 Ref: Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. PMID: 21207374 Ref: Oncogenic Ras/Src cooperativity in pancreatic neoplasia. PMID: 21242978 Ref: DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. PMID: 21285251 Ref: Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. PMID: 21289082 Ref: Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. PMID: 21298467 Ref: Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PMID: 21304978 Ref: Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PMID: 21311774 Ref: Activated KrasG(1)(2)D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. PMID: 21364589 Ref: Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. PMID: 21385921 Ref: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. PMID: 21481788 Ref: Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials. PMID: 21521159 Ref: Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. PMID: 21572398 Ref: Plasma proteome profiles associated with inflammation, angiogenesis, and cancer. PMID: 21589862 Ref: Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. PMID: 21611090 Ref: Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. PMID: 21611096 Ref: Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. PMID: 21622730 Ref: [New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis]. PMID: 21664851 Ref: Early requirement of Rac1 in a mouse model of pancreatic cancer. PMID: 21684285 Ref: Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PMID: 21698197 Ref: Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. PMID: 21699781 Ref: Hedgehog signaling and pancreatic tumor development. PMID: 21704226 Ref: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. PMID: 21734707 Ref: Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PMID: 21738581 Ref: From tissue turnover to the cell of origin for pancreatic cancer. PMID: 21750515 Ref: Establishment and characterization of a new cell line, A99, from a primary small cell carcinoma of the pancreas. PMID: 21768923 Ref: MicroRNA-375 and MicroRNA-221: Potential Noncoding RNAs Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer. PMID: 21779484 Ref: Emerging pathways and future targets for the molecular therapy of pancreatic cancer. PMID: 21819318 Ref: MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-beta signaling. PMID: 21856775 Ref: Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. PMID: 21862683 Ref: Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. PMID: 21876563 Ref: KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. PMID: 21894049 Ref: Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. PMID: 21945955 Ref: Screening pancreatic oncogenes in zebrafish using the Gal4/UAS system. PMID: 21951538 Ref: EUS-FNA mutational analysis in differentiating autoimmune pancreatitis and pancreatic cancer. PMID: 21997479 Ref: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. PMID: 21998291 Ref: Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. PMID: 22056382 Ref: Novel mutations of PRSS1 gene in patients with pancreatic cancer among Han population. PMID: 22088471 Ref: Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. PMID: 22113502 Ref: Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PMID: 22140463 Ref: Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy. PMID: 22292129 Ref: [Colloid carcinoma of pancreas: a clinicopathologic study of 4 cases]. PMID: 22336159 Ref: [Detection of KRAS mutations in tumor cells using biochips]. PMID: 22393783 Ref: Kras, Pten, NF-kappaB, and inflammation: dangerous liaisons. PMID: 22586351 Ref: Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. PMID: 22977607 Ref: Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. PMID: 24212643 Ref: Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. PMID: 24212645 |
Ref: Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. PMID: 21683373 Ref: A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. PMID: 21996748 Ref: Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. PMID: 22041919 Ref: RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. PMID: 22052106 Ref: Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia. PMID: 22056954 Ref: Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. PMID: 22083596 Ref: GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. PMID: 22086851 Ref: Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. PMID: 22099597 Ref: Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. PMID: 22128300 Ref: Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. PMID: 22157328 Ref: N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer. PMID: 22158044 Ref: Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. PMID: 22167000 Ref: Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. PMID: 22190076 Ref: Genomic sequencing of key genes in mouse pancreatic cancer cells. PMID: 22208613 Ref: Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. PMID: 22222635 Ref: Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. PMID: 22232209 Ref: Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. PMID: 22234980 Ref: Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. PMID: 22287227 Ref: Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients. PMID: 22310974 Ref: Bone marrow-derived proangiogenic cells in pancreatic cancer. PMID: 22320912 Ref: MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PMID: 22384141 Ref: Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. PMID: 22411900 Ref: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. PMID: 22421440 Ref: EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. PMID: 22422135 Ref: Molecular pathology of pancreatic cancer: from bench-to-bedside translation. PMID: 22458520 Ref: Tif1gamma suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway. PMID: 22469842 Ref: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. PMID: 22472349 Ref: The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. PMID: 22493246 Ref: Comparison of the chemosensitivity of the primary lesion and a pancreatic metastasis of colon cancer: a case report. PMID: 22493386 Ref: Mouse models of pancreatic cancer. PMID: 22493542 Ref: The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. PMID: 22509024 Ref: Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. PMID: 22517373 Ref: Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. PMID: 22541435 Ref: Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. PMID: 22547163 Ref: Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. PMID: 22565310 Ref: Pancreatic cancer: Mouse models link metabolism and deubiquitination with Kras. PMID: 22584999 Ref: KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. PMID: 22589274 Ref: GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. PMID: 22671702 Ref: Silencing the killers: paracrine immune suppression in pancreatic cancer. PMID: 22698396 Ref: Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. PMID: 22698407 Ref: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. PMID: 22699621 Ref: AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. PMID: 22722139 Ref: Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. PMID: 22723370 Ref: Changes in connexin43 expression and localization during pancreatic cancer progression. PMID: 22729649 Ref: Targeting eNOS in pancreatic cancer. PMID: 22738914 Ref: Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. PMID: 22745110 Ref: Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. PMID: 22750975 Ref: Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. PMID: 22759592 Ref: Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. PMID: 22762308 Ref: Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma. PMID: 22797009 Ref: The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells. PMID: 22820191 Ref: Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. PMID: 22833572 Ref: Loss of miR-126 is crucial to pancreatic cancer progression. PMID: 22845403 Ref: Molecular analysis of centrifugation supernatant fluid from pancreaticobiliary duct samples can improve cancer detection. PMID: 22846349 Ref: Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis. PMID: 22848379 Ref: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. PMID: 22851141 Ref: Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. PMID: 22868929 Ref: KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. PMID: 22871572 Ref: Conceptual framework for cutting the pancreatic cancer fuel supply. PMID: 22896695 Ref: Ready, set, go: the EGF receptor at the pancreatic cancer starting line. PMID: 22975369 Ref: EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. PMID: 22975375 Ref: Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. PMID: 22991414 Ref: Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. PMID: 23019409 Ref: Reovirus: a targeted therapeutic--progress and potential. PMID: 23038811 Ref: miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. PMID: 23070684 Ref: A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. PMID: 23076356 Ref: Gene therapy of pancreatic cancer targeting the K-Ras oncogene. PMID: 23099885 Ref: Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. PMID: 23102107 Ref: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. PMID: 23103869 Ref: MSX2 in pancreatic tumor development and its clinical application for the diagnosis of pancreatic ductal adenocarcinoma. PMID: 23162473 Ref: KRAS above and beyond - EGFR in pancreatic cancer. PMID: 23174662 Ref: Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration. PMID: 23197977 Ref: Etiology and oncogenesis of pancreatic carcinoma. PMID: 23213974 Ref: Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PMID: 23226501 Ref: Pancreatic cancer and diabetes. PMID: 23393682 |
Ref: Regulation of pancreatic cancer growth by superoxide. PMID: 22392697 Ref: Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice. PMID: 22549877 Ref: Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. PMID: 22699205 Ref: RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. PMID: 22751122 Ref: Requirement of NEMO/IKKgamma for effective expansion of KRAS-induced precancerous lesions in the pancreas. PMID: 22751123 Ref: Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). PMID: 22773551 Ref: AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. PMID: 22945649 Ref: Involvement of oncogenic K-ras on cell migration stimulated by lysophosphatidic acid receptor-2 in pancreatic cancer cells. PMID: 23041208 Ref: Genetic and epigenetic markers in the evaluation of pancreatic masses. PMID: 23135349 Ref: EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. PMID: 23169292 Ref: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. PMID: 23211371 Ref: Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. PMID: 23237571 Ref: Association between KRAS mutation, detected in pancreatic cyst fluid, and long-term outcomes of patients. PMID: 23267865 Ref: Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo. PMID: 23288781 Ref: Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E delta-tocotrienol. PMID: 23302291 Ref: Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome. PMID: 23303473 Ref: Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. PMID: 23333712 Ref: Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. PMID: 23344532 Ref: The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. PMID: 23355395 Ref: Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. PMID: 23361300 Ref: Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. PMID: 23378339 Ref: Outlier kinase expression by RNA sequencing as targets for precision therapy. PMID: 23384775 Ref: Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. PMID: 23403822 Ref: Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features. PMID: 23425895 Ref: Biodegradable nanocapsules as siRNA carriers for mutant K-Ras gene silencing of human pancreatic carcinoma cells. PMID: 23427041 Ref: KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. PMID: 23435671 Ref: PARI overexpression promotes genomic instability and pancreatic tumorigenesis. PMID: 23436799 Ref: Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. PMID: 23441129 Ref: Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. PMID: 23467612 Ref: Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. PMID: 23470560 Ref: MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. PMID: 23471001 Ref: Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. PMID: 23475955 Ref: Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. PMID: 23482563 Ref: KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer. PMID: 23486365 Ref: Genetically engineered mouse models of pancreatic adenocarcinoma. PMID: 23506980 Ref: BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. PMID: 23530562 Ref: Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. PMID: 23532108 Ref: GSK-3alpha promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-kappaB. PMID: 23547054 Ref: Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS. PMID: 23558076 Ref: Somatic mutations in exocrine pancreatic tumors: association with patient survival. PMID: 23565280 Ref: Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas. PMID: 23578383 Ref: Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7. PMID: 23588713 Ref: Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. PMID: 23590467 Ref: In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status. PMID: 23590868 Ref: KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. PMID: 23599154 Ref: Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae. PMID: 23613993 Ref: Roles for KRAS in pancreatic tumor development and progression. PMID: 23622131 Ref: PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. PMID: 23696215 Ref: Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation. PMID: 23712558 Ref: Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer. PMID: 23746401 Ref: A new alpha in line between KRAS and NF-kappaB activation? PMID: 23749528 Ref: PanIN-specific regulation of Wnt signaling by HIF2alpha during early pancreatic tumorigenesis. PMID: 23749643 Ref: Snail cooperates with KrasG12D to promote pancreatic fibrosis. PMID: 23761168 Ref: Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. PMID: 23774697 Ref: Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. PMID: 23786654 Ref: Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. PMID: 23808822 Ref: Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PMID: 23840665 Ref: Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. PMID: 23868061 Ref: The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. PMID: 23887057 Ref: Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. PMID: 23893923 Ref: Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. PMID: 23912084 Ref: Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. PMID: 23918833 Ref: [Intraductal tubulopapillary neoplasm of the pancreas: a clinicopathologic study of 6 cases]. PMID: 23928532 Ref: The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. PMID: 23934321 Ref: Vitamin E delta-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. PMID: 23963802 Ref: Dietary energy balance modulation of Kras- and Ink4a/Arf+/--driven pancreatic cancer: the role of insulin-like growth factor-I. PMID: 23980075 Ref: Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. PMID: 23989613 Ref: DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PMID: 24040120 Ref: Integrative genomic and functional profiling of the pancreatic cancer genome. PMID: 24041470 Ref: Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras. PMID: 24041692 Ref: TLR7 inhibition: A novel strategy for pancreatic cancer treatment? PMID: 24058792 Ref: Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. PMID: 24075515 Ref: Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. PMID: 24097820 Ref: Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PMID: 24130864 Ref: Pancreatic cancer: modulation of KRAS, MicroRNAs, and intercellular communication in the setting of tumor heterogeneity. PMID: 24152947 Ref: Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PMID: 24194913 Ref: [Will molecular diagnostics become established in pancreatic pathology?]. PMID: 24196616 Ref: A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. PMID: 24204197 Ref: Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PMID: 24204737 Ref: Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. PMID: 24216479 Ref: mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. PMID: 24231729 Ref: Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PMID: 24278292 Ref: [Kras oncogene and pancreatic cancer: thirty years after]. PMID: 24280502 Ref: Mutant KRAS is a druggable target for pancreatic cancer. PMID: 24297898 Ref: p53 status determines the role of autophagy in pancreatic tumour development. PMID: 24305049 Ref: Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. PMID: 24403857 Ref: Risk factors for pancreatic cancer: underlying mechanisms and potential targets. PMID: 24474939 Ref: Kras as a key oncogene and therapeutic target in pancreatic cancer. PMID: 24478710 Ref: Pancreatic Acinar Cell 3-Dimensional Culture. PMID: 27453905 |
Ref: Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. PMID: 23376846 Ref: Pancreatic tumours escape from translational control through 4E-BP1 loss. PMID: 23563181 Ref: Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis. PMID: 23598351 Ref: Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation. PMID: 23645620 Ref: EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. PMID: 23752186 Ref: KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. PMID: 23887294 Ref: Pancreatic cancer in the remnant pancreas following primary pancreatic resection. PMID: 23975591 Ref: Identification and manipulation of biliary metaplasia in pancreatic tumors. PMID: 23999170 Ref: Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. PMID: 24026351 Ref: Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. PMID: 24028894 Ref: SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. PMID: 24067278 Ref: Activated wnt signaling in stroma contributes to development of pancreatic mucinous cystic neoplasms. PMID: 24067880 Ref: Cholecystokinin and pancreatic cancer: the chicken or the egg? PMID: 24177032 Ref: Pathogenesis of pancreatic cancer: lessons from animal models. PMID: 24178582 Ref: Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. PMID: 24189171 Ref: Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. PMID: 24222664 Ref: Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. PMID: 24240689 Ref: MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. PMID: 24315826 Ref: Translational research in pancreatic cancer: KRAS and beyond. PMID: 24326376 Ref: Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. PMID: 24371225 Ref: KRAS: feeding pancreatic cancer proliferation. PMID: 24388967 Ref: Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment. PMID: 24389175 Ref: A modular and flexible ESC-based mouse model of pancreatic cancer. PMID: 24395249 Ref: Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. PMID: 24398677 Ref: Molecular genetics of pancreatic neoplasms and their morphologic correlates: an update on recent advances and potential diagnostic applications. PMID: 24436263 Ref: Case report: Intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype. PMID: 24443801 Ref: Genetic progression of pancreatic cancer. PMID: 24445769 Ref: Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. PMID: 24462734 Ref: Molecular pathology of pancreatic cancer. PMID: 24471965 Ref: STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. PMID: 24484537 Ref: Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. PMID: 24491405 Ref: The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. PMID: 24518495 Ref: PIK3CA mutations in mucinous cystic neoplasms of the pancreas. PMID: 24518503 Ref: Multimodal molecular imaging of integrin alphavbeta3 for in vivo detection of pancreatic cancer. PMID: 24549287 Ref: Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. PMID: 24550494 Ref: Detection of circulating tumor DNA in early- and late-stage human malignancies. PMID: 24553385 Ref: Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma. PMID: 24568222 Ref: Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. PMID: 24604757 Ref: Pharmacogenomics update in pancreatic cancer. PMID: 24618431 Ref: Pancreatic cancer-induced cachexia is Jak2-dependent in mice. PMID: 24648112 Ref: Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies. PMID: 24670819 Ref: KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. PMID: 24681874 Ref: Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. PMID: 24681997 Ref: Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. PMID: 24691445 Ref: Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. PMID: 24694735 Ref: Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. PMID: 24713432 Ref: Targeting mTOR dependency in pancreatic cancer. PMID: 24717934 Ref: Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. PMID: 24722285 Ref: SULF1/SULF2 splice variants differentially regulate pancreatic tumour growth progression. PMID: 24726914 Ref: Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. PMID: 24737325 Ref: The complex landscape of pancreatic cancer metabolism. PMID: 24743516 Ref: An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. PMID: 24747441 Ref: Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. PMID: 24752990 Ref: Oncogenic KRAS signalling in pancreatic cancer. PMID: 24755884 Ref: Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. PMID: 24788257 Ref: CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. PMID: 24795355 Ref: Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo. PMID: 24799381 Ref: Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras. PMID: 24823632 Ref: Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. PMID: 24827134 Ref: Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. PMID: 24850902 Ref: A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. PMID: 24857345 Ref: Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. PMID: 24874484 Ref: Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. PMID: 24875860 Ref: Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer. PMID: 24878567 Ref: XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. PMID: 24880079 Ref: Genetic inactivation of the pancreatitis-inducible gene Nupr1 impairs PanIN formation by modulating Kras(G12D)-induced senescence. PMID: 24902898 Ref: A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. PMID: 24915778 Ref: Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPalpha. PMID: 24947179 Ref: Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer. PMID: 24953430 Ref: Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. PMID: 24954535 Ref: Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PMID: 24978597 Ref: Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. PMID: 24998203 Ref: Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. PMID: 25003666 Ref: Stromal response to Hedgehog signaling restrains pancreatic cancer progression. PMID: 25024225 Ref: A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma. PMID: 25042889 Ref: Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. PMID: 25050737 Ref: Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. PMID: 25058882 Ref: KRAS in pancreatic cancer. PMID: 25076326 Ref: Interleukin-6: a villain in the drama of pancreatic cancer development and progression. PMID: 25100121 Ref: The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling. PMID: 25104358 Ref: Adjusting serum concentrations of organochlorine compounds by lipids and symptoms: a causal framework for the association with K-ras mutations in pancreatic cancer. PMID: 25113205 Ref: Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. PMID: 25117978 Ref: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. PMID: 25119024 Ref: Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. PMID: 25127677 Ref: Emerging role of the KRAS-PDK1 axis in pancreatic cancer. PMID: 25152578 Ref: Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. PMID: 25152579 Ref: Novel therapeutic targets for pancreatic cancer. PMID: 25152585 Ref: KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. PMID: 25167228 Ref: The increasing diversity of KRAS signaling in pancreatic cancer. PMID: 25167989 Ref: HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. PMID: 25199993 Ref: Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity. PMID: 25216706 Ref: Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. PMID: 25248858 Ref: IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. PMID: 25250570 Ref: A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. PMID: 25261239 Ref: Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. PMID: 25261994 Ref: Intraductal neoplasms of the pancreas. PMID: 25282472 Ref: Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway. PMID: 25304374 Ref: Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. PMID: 25306215 Ref: Gene therapy in pancreatic cancer. PMID: 25309069 Ref: PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. PMID: 25311989 Ref: RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. PMID: 25341034 Ref: Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer. PMID: 25347530 Ref: The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer. PMID: 25380065 Ref: Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. PMID: 25393586 Ref: Epithelial Notch signaling is a limiting step for pancreatic carcinogenesis. PMID: 25416148 Ref: Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis. PMID: 25419353 Ref: Differential expression of GNAS and KRAS mutations in pancreatic cysts. PMID: 25435574 Ref: Pathology and genetics of pancreatic neoplasms with acinar differentiation. PMID: 25441307 Ref: Arrested development and the great escape--the role of cellular senescence in pancreatic cancer. PMID: 25461770 Ref: Critical role of NF-kappaB in pancreatic cancer. PMID: 25473891 Ref: MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. PMID: 25497091 Ref: Diagnosis and molecular aspects of solid-pseudopapillary neoplasms of the pancreas. PMID: 25524568 Ref: [Genetic aspects of pancreatic cancer]. PMID: 25911935 |
Ref: Molecular landscape of pancreatic cancer: implications for current clinical trials. PMID: 11051691 Ref: Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis. PMID: 24561527 Ref: miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. PMID: 24608432 Ref: Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer. PMID: 24704294 Ref: Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. PMID: 24791855 Ref: Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. PMID: 24798941 Ref: Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. PMID: 25065594 Ref: Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. PMID: 25081753 Ref: Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. PMID: 25091263 Ref: Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. PMID: 25103069 Ref: Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? PMID: 25142799 Ref: Familial and sporadic pancreatic cancer share the same molecular pathogenesis. PMID: 25240578 Ref: Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway. PMID: 25305448 Ref: Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. PMID: 25322341 Ref: Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. PMID: 25348516 Ref: Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. PMID: 25361845 Ref: Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. PMID: 25376606 Ref: Basaloid carcinoma of the pancreas--clinicopathological presentation and oncogenetic snapshot of a rare entity. PMID: 25432630 Ref: Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. PMID: 25453266 Ref: Ablation of 5-lipoxygenase mitigates pancreatic lesion development. PMID: 25454978 Ref: Intraductal papillary mucinous neoplasm in a neonate with congenital hyperinsulinism and a de novo germline SKIL gene mutation. PMID: 25464936 Ref: Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia. PMID: 25466963 Ref: KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. PMID: 25481712 Ref: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. PMID: 25500057 Ref: MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. PMID: 25500542 Ref: Targeting protein kinase C subtypes in pancreatic cancer. PMID: 25604078 Ref: Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. PMID: 25612765 Ref: Survival in ampullary cancer: potential role of different KRAS mutations. PMID: 25616942 Ref: NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. PMID: 25623042 Ref: Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. PMID: 25623214 Ref: Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. PMID: 25623216 Ref: ADAM8 as a drug target in pancreatic cancer. PMID: 25629724 Ref: Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. PMID: 25644265 Ref: Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas. PMID: 25656048 Ref: Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. PMID: 25683115 Ref: Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. PMID: 25687883 Ref: Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. PMID: 25698580 Ref: Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. PMID: 25699241 Ref: Molecular landscape of pancreatic cancer: implications for current clinical trials. PMID: 25714017 Ref: Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method. PMID: 25724428 Ref: Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. PMID: 25736685 Ref: Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression. PMID: 25748236 Ref: ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. PMID: 25753158 Ref: TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. PMID: 25762644 Ref: Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. PMID: 25766633 Ref: Allelic ratio of KRAS mutations in pancreatic cancer. PMID: 25777349 Ref: GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. PMID: 25796395 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: Circulating tumor cells found in patients with localized and advanced pancreatic cancer. PMID: 25822154 Ref: Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. PMID: 25823825 Ref: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. PMID: 25855536 Ref: Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide. PMID: 25875797 Ref: Metformin suppresses pancreatic tumor growth with inhibition of NFkappaB/STAT3 inflammatory signaling. PMID: 25875801 Ref: Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. PMID: 25888329 Ref: Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. PMID: 25896973 Ref: Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer. PMID: 25897428 Ref: Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer. PMID: 25905463 Ref: Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. PMID: 25931518 Ref: Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. PMID: 25939753 Ref: Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. PMID: 25952647 Ref: Selective killing of K-ras-transformed pancreatic cancer cells by targeting NAD(P)H oxidase. PMID: 25963558 Ref: Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. PMID: 25977335 Ref: Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. PMID: 25992771 Ref: [Treatment of pancreatic cancer. Actuality and perspective]. PMID: 25994537 Ref: Obesity, Intrapancreatic Fatty Infiltration, and Pancreatic Cancer. PMID: 25995340 Ref: EGR-1/Bax pathway plays a role in vitamin E delta-tocotrienol-induced apoptosis in pancreatic cancer cells. PMID: 25997867 Ref: RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. PMID: 26004068 Ref: RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. PMID: 26009994 Ref: New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. PMID: 26023084 Ref: U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model. PMID: 26035715 Ref: Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. PMID: 26036346 Ref: Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. PMID: 26046796 Ref: Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. PMID: 26077591 Ref: A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. PMID: 26077929 Ref: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. PMID: 26091808 Ref: Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. PMID: 26097885 Ref: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. PMID: 26106858 Ref: Keap1-Nrf2 signalling in pancreatic cancer. PMID: 26117456 Ref: [Advance in the biology of pancreatic of cancer]. PMID: 26118878 Ref: Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines. PMID: 26124327 Ref: In vivo(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography imaging of pancreatic tumors in a transgenic rat model carrying the human KRAS(G12V) oncogene. PMID: 26137023 Ref: The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. PMID: 26151762 Ref: The crosstalk between acinar cells with Kras mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions. PMID: 26155420 Ref: The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. PMID: 26156229 Ref: A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. PMID: 26158412 Ref: Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. PMID: 26158861 Ref: Targeting cancer cell metabolism in pancreatic adenocarcinoma. PMID: 26164081 Ref: Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules. PMID: 26169922 Ref: Protein kinase D enzymes: novel kinase targets in pancreatic cancer. PMID: 26174103 Ref: Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. PMID: 26178787 Ref: Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. PMID: 26185420 Ref: Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway. PMID: 26199979 Ref: Assembling Mn:ZnSe quantum dots-siRNA nanoplexes for gene silencing in tumor cells. PMID: 26214202 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: A combination of molecular markers and clinical features improve the classification of pancreatic cysts. PMID: 26253305 Ref: Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. PMID: 26255562 Ref: Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. PMID: 26257206 Ref: Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer. PMID: 26359451 Ref: Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. PMID: 26380056 Ref: IL17 Functions through the Novel REG3beta-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. PMID: 26404002 Ref: Multistep, effective drug distribution within solid tumors. PMID: 26416413 Ref: GEMMs as preclinical models for testing pancreatic cancer therapies. PMID: 26438692 Ref: PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. PMID: 26451606 Ref: Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. PMID: 26452217 Ref: Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. PMID: 26452271 Ref: Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. PMID: 26462257 Ref: Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature. PMID: 26464736 Ref: The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-kappaB and RalB signaling pathways. PMID: 26477488 Ref: Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. PMID: 26479921 Ref: Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. PMID: 26498594 Ref: MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. PMID: 26505547 Ref: Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways. PMID: 26512205 Ref: Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. PMID: 26516699 Ref: Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. PMID: 26527777 Ref: Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. PMID: 26555578 Ref: Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. PMID: 26575024 Ref: A case of MUC5AC-positive intraductal neoplasm of the pancreas classified as an intraductal tubulopapillary neoplasm? PMID: 26586167 Ref: Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. PMID: 26605280 Ref: Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation. PMID: 26617245 Ref: Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. PMID: 26669280 Ref: Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs). PMID: 27499895 Ref: Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer. PMID: 28162272 |
Ref: Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer. PMID: 26279302 Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS. PMID: 26408346 Ref: APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice. PMID: 26411367 Ref: Intraductal tubulopapillary neoplasm of the bile duct: A case report and review of the published work. PMID: 26459784 Ref: IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-kappaB Activation. PMID: 26500238 Ref: Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer. PMID: 26572242 Ref: A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. PMID: 26582596 Ref: p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. PMID: 26592447 Ref: Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. PMID: 26616862 Ref: Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia. PMID: 26626780 Ref: Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. PMID: 26668065 Ref: Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM. PMID: 26683769 Ref: Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure. PMID: 26684859 Ref: NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. PMID: 26697077 Ref: Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. PMID: 26701267 Ref: A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies. PMID: 26704357 Ref: Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. PMID: 26715642 Ref: IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. PMID: 26715643 Ref: Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. PMID: 26716510 Ref: Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. PMID: 26716649 Ref: Microarray-based gene expression profiling reveals genes and pathways involved in the oncogenic function of REG3A on pancreatic cancer cells. PMID: 26719042 Ref: Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. PMID: 26725216 Ref: Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. PMID: 26725968 Ref: Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. PMID: 26732095 Ref: Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. PMID: 26735353 Ref: HDAC3 mediates smoking-induced pancreatic cancer. PMID: 26745602 Ref: Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1. PMID: 26747707 Ref: Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 >/= 1,000 U/mL. PMID: 26753987 Ref: Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. PMID: 26755660 Ref: Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. PMID: 26762195 Ref: Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors. PMID: 26767919 Ref: CXCR2 signaling regulates KRAS(G(1)(2)D)-induced autocrine growth of pancreatic cancer. PMID: 26771140 Ref: [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]. PMID: 26790710 Ref: GSK-3beta Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. PMID: 26823495 Ref: Pancreatic cancer. PMID: 26830752 Ref: Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. PMID: 26835979 Ref: Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. PMID: 26847682 Ref: Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. PMID: 26880801 Ref: MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. PMID: 26884312 Ref: [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass]. PMID: 26898792 Ref: Telomerase activity in pancreatic juice differentiates pancreatic cancer from chronic pancreatitis: A meta-analysis. PMID: 26899542 Ref: Genomic analyses identify molecular subtypes of pancreatic cancer. PMID: 26909576 Ref: Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. PMID: 26916719 Ref: Changing the course of pancreatic cancer--Focus on recent translational advances. PMID: 26924195 Ref: KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. PMID: 26927447 Ref: Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. PMID: 26929329 Ref: Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling. PMID: 26939707 Ref: Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. PMID: 26946344 Ref: Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions. PMID: 26947075 Ref: Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma. PMID: 26967456 Ref: Clinicopathological Implications of Wingless/int1 (WNT) Signaling Pathway in Pancreatic Ductal Adenocarcinoma. PMID: 26972939 Ref: KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis. PMID: 26977883 Ref: FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. PMID: 26983463 Ref: Developments in miRNA gene signaling pathways in pancreatic cancer. PMID: 26984178 Ref: Prox1-Heterozygosis Sensitizes the Pancreas to Oncogenic Kras-Induced Neoplastic Transformation. PMID: 26992918 Ref: Novel Methodology for Rapid Detection of KRAS Mutation Using PNA-LNA Mediated Loop-Mediated Isothermal Amplification. PMID: 26999437 Ref: Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. PMID: 27003603 Ref: Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both? PMID: 27011047 Ref: p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. PMID: 27032419 Ref: Use of molecular studies for treatment of metastatic pleomorphic large cell pancreatic cancers-a novel strategy. PMID: 27034802 Ref: Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. PMID: 27034805 Ref: PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. PMID: 27058416 Ref: Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. PMID: 27058937 Ref: Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. PMID: 27067801 Ref: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. PMID: 27089513 Ref: Identification of pyrazolopyridazinones as PDEdelta inhibitors. PMID: 27094677 Ref: Targeting inflammation in pancreatic cancer: Clinical translation. PMID: 27096033 Ref: KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. PMID: 27096871 Ref: Critical role of oncogenic KRAS in pancreatic cancer (Review). PMID: 27121414 Ref: Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. PMID: 27122185 Ref: Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice. PMID: 27138793 Ref: Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. PMID: 27147553 Ref: Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor. PMID: 27149134 Ref: Pancreatic cancer. PMID: 27158978 Ref: Role of TFEB-driven autophagy regulation in pancreatic cancer treatment. PMID: 27175909 Ref: Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis. PMID: 27183870 Ref: Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. PMID: 27196585 Ref: Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. PMID: 27210037 Ref: YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. PMID: 27215660 Ref: K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. PMID: 27225938 Ref: Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. PMID: 27233476 Ref: Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. PMID: 27248578 Ref: Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. PMID: 27256393 Ref: Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma. PMID: 27262570 Ref: Combined targeting of TGF-beta, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. PMID: 27267807 Ref: Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. PMID: 27280632 Ref: The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR PMID: 27289344 Ref: KRAS Mutations in Canine and Feline Pancreatic Acinar Cell Carcinoma. PMID: 27290644 Ref: Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas. PMID: 27295533 Ref: A bright future for protein kinase D1 as a drug target to prevent or treat pancreatic cancer. PMID: 27308552 Ref: ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. PMID: 27318148 Ref: A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. PMID: 27322423 Ref: Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. PMID: 27323830 Ref: Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells. PMID: 27333990 Ref: Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. PMID: 27336608 Ref: A combinatorial strategy for treating KRAS-mutant lung cancer. PMID: 27338794 Ref: Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia. PMID: 27364947 Ref: Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. PMID: 27375074 Ref: Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. PMID: 27376576 Ref: Concepts to Target MYC in Pancreatic Cancer. PMID: 27406986 Ref: The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. PMID: 27415425 Ref: Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. PMID: 27461042 Ref: Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. PMID: 27471630 Ref: NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. PMID: 27477511 Ref: Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines. PMID: 27494181 Ref: Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver. PMID: 27506299 Ref: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. PMID: 27520560 Ref: Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer. PMID: 27539232 Ref: Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. PMID: 27550813 Ref: Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. PMID: 27585860 Ref: Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. PMID: 27591291 Ref: KRAS-related proteins in pancreatic cancer. PMID: 27595930 Ref: APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors. PMID: 27602165 Ref: Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. PMID: 27609895 Ref: Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. PMID: 27610015 Ref: alpha-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice. PMID: 27624879 Ref: Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. PMID: 27633013 Ref: The PRKD1 promoter is a target of the KRas-NF-kappaB pathway in pancreatic cancer. PMID: 27649783 Ref: Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. PMID: 27659014 Ref: The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. PMID: 27659181 Ref: Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? PMID: 27689078 Ref: KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. PMID: 27705932 Ref: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. PMID: 27732578 Ref: CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. PMID: 27737879 Ref: Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer. PMID: 27753011 Ref: Fbxw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation. PMID: 27764699 Ref: Quantitative assessment of pancreatic cancer precursor lesions in IHC-stained tissue with a tissue image analysis platform. PMID: 27775692 Ref: Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation. PMID: 27810244 Ref: Autophagy Induced during Pancreatitis Promotes KRAS-Dependent Transformation in the Pancreas. PMID: 27833900 Ref: GLI1, a master regulator of the hallmark of pancreatic cancer. PMID: 27862693 Ref: Genetics of Pancreatic Cancer and Its Implications on Therapy. PMID: 27865273 Ref: Molecular Pathogenesis of Pancreatic Cancer. PMID: 27865459 Ref: Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. PMID: 27889645 Ref: Activation of WNT/beta-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61. PMID: 27889647 Ref: [A Novel Treatment Strategy for Pancreatic Cancer Based on Gene Profiles]. PMID: 27899773 Ref: Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. PMID: 27919956 Ref: Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells. PMID: 27929127 Ref: EUS for pancreatic cystic neoplasms: The roadmap to the future is much more than just a few shades of gray. PMID: 27955751 Ref: A new PDAC mouse model originated from iPSCs-converted pancreatic cancer stem cells (CSCcm). PMID: 28042501 Ref: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. PMID: 28874965 |
Ref: Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. PMID: 27013602 Ref: KRas, ROS and the initiation of pancreatic cancer. PMID: 27215184 Ref: Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[alpha]phenoxazines Derivatives, 10-methyl-benzo[alpha]phenoxazine-5-one and benzo[alpha]phenoxazine-5-one. PMID: 27349450 Ref: Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. PMID: 27354473 Ref: Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. PMID: 27402485 Ref: IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. PMID: 27435400 Ref: Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma. PMID: 27542263 Ref: Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. PMID: 27573236 Ref: The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cells. PMID: 27583552 Ref: A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. PMID: 27602776 Ref: Mutant p53 Together with TGFbeta Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. PMID: 27637888 Ref: Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. PMID: 27725226 Ref: EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo. PMID: 27739365 Ref: Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. PMID: 27779106 Ref: KRAS/NF-kappaB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. PMID: 27793842 Ref: An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer. PMID: 27835861 Ref: Targeting reactive oxygen species in development and progression of pancreatic cancer. PMID: 27841037 Ref: Critical role of hnRNP A1 in activating KRAS transcription in pancreatic cancer cells: A molecular mechanism involving G4 DNA. PMID: 27888145 Ref: TGFbeta promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1. PMID: 27893715 Ref: ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. PMID: 27941872 Ref: Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. PMID: 27975152 Ref: Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. PMID: 27978579 Ref: ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. PMID: 28025100 Ref: ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. PMID: 28031255 Ref: Elevation of beta-galactoside alpha2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis. PMID: 28032597 Ref: Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells. PMID: 28060183 Ref: IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis. PMID: 28069799 Ref: Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer. PMID: 28077300 Ref: Stromal cues regulate the pancreatic cancer epigenome and metabolome. PMID: 28096419 Ref: Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. PMID: 28099251 Ref: High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. PMID: 28104621 Ref: Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. PMID: 28108627 Ref: Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. PMID: 28121262 Ref: PKR2 and beta-catenin genes regulates pancreatic cancer chemosensitivity. PMID: 28121357 Ref: Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. PMID: 28125909 Ref: Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. PMID: 28139399 Ref: Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis. PMID: 28141826 Ref: Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. PMID: 28160167 Ref: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. PMID: 28178232 Ref: ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. PMID: 28178529 Ref: Team work and cytopathology molecular diagnosis of solid pancreatic lesions. PMID: 28190274 Ref: BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. PMID: 28194432 Ref: Methylation of Tumor Suppressor Genes in Autoimmune Pancreatitis. PMID: 28196014 Ref: Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. PMID: 28198009 Ref: An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. PMID: 28220783 Ref: Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers. PMID: 28249168 Ref: Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells. PMID: 28272465 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. PMID: 28315323 Ref: KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test. PMID: 28331530 Ref: Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. PMID: 28366542 Ref: [Autophagy contributes to the initiation of pancreatic cancer]. PMID: 28367822 Ref: Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". PMID: 28373361 Ref: U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts. PMID: 28377488 Ref: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. PMID: 28389707 Ref: Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. PMID: 28414297 Ref: The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. PMID: 28414315 Ref: Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells. PMID: 28414320 Ref: MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression. PMID: 28415794 Ref: Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. PMID: 28419443 Ref: Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. PMID: 28435405 Ref: SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer. PMID: 28435453 Ref: Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer. PMID: 28446878 Ref: Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. PMID: 28449008 Ref: KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. PMID: 28450086 Ref: KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. PMID: 28452926 Ref: Effect of cigarette smoke exposure and mutant Kras overexpression on pancreatic cell proliferation. PMID: 28454347 Ref: Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. PMID: 28455360 Ref: Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. PMID: 28456055 Ref: LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer. PMID: 28475592 Ref: Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse. PMID: 28510280 Ref: The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis. PMID: 28514653 Ref: Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo. PMID: 28554668 Ref: Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. PMID: 28574828 Ref: A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. PMID: 28576749 Ref: Pancreatic cancer heterogeneity and response to Mek inhibition. PMID: 28581516 Ref: Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species. PMID: 28581519 Ref: KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model. PMID: 28581520 Ref: BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. PMID: 28591720 Ref: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. PMID: 28607485 Ref: Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. PMID: 28611197 Ref: All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS. PMID: 28616588 Ref: Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. PMID: 28619758 Ref: Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPalpha-saRNA. PMID: 28639199 Ref: Targeting metabolic reprogramming in KRAS-driven cancers. PMID: 28647837 Ref: Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. PMID: 28656876 Ref: Pancreas specific expression of oncogenes in a porcine model. PMID: 28664456 Ref: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. PMID: 28674438 Ref: Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. PMID: 28675654 Ref: An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues. PMID: 28691390 Ref: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells. PMID: 28692035 Ref: Neat1 is a p53-inducible lincRNA essential for transformation suppression. PMID: 28698299 Ref: Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges. PMID: 28705806 Ref: Establishment and characterization of a novel murine model of pancreatic cancer cachexia. PMID: 28730707 Ref: Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. PMID: 28732488 Ref: Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. PMID: 28738823 Ref: Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease. PMID: 28741619 Ref: Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas. PMID: 28742845 Ref: A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. PMID: 28746882 Ref: Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRAS(G12D)-driven Pancreatic Tumorigenesis. PMID: 28752115 Ref: FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. PMID: 28765935 Ref: The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. PMID: 28796802 Ref: Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. PMID: 28801547 Ref: c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice. PMID: 28837246 Ref: [Resection of main duct and mixed type IPMN >/=5 mm]. PMID: 28842734 Ref: Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles. PMID: 28849098 Ref: RAGE maintains high levels of NFkappaB and oncogenic Kras activity in pancreatic cancer. PMID: 28867179 Ref: Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells. PMID: 28867190 Ref: Dissection of the Mouse Pancreas for Histological Analysis and Metabolic Profiling. PMID: 28872120 Ref: Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. PMID: 28874546 Ref: Pancreatic cancer: Exosomes for targeting KRAS in the treatment of pancreatic cancer. PMID: 28874835 Ref: Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. PMID: 28886117 Ref: Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. PMID: 28893801 Ref: ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer. PMID: 28894253 Ref: Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. PMID: 28915575 Ref: Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele. PMID: 28934293 Ref: ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis. PMID: 28942143 Ref: Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers. PMID: 28954733 Ref: Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. PMID: 28957417 Ref: Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. PMID: 28961832 Ref: Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. PMID: 28980940 Ref: Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. PMID: 28986391 Ref: Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer. PMID: 29050937 Ref: Survival of pancreatic cancer cells lacking KRAS function. PMID: 29061961 Ref: KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. PMID: 29079305 Ref: Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. PMID: 29079791 Ref: Genetic basis of a common tumor origin in the development of pancreatic mixed acinar-neuroendocrine-ductal carcinoma: A case report. PMID: 29085438 Ref: Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. PMID: 29085567 Ref: STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. PMID: 29108249 Ref: Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. PMID: 29113235 Ref: A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. PMID: 29137355 Ref: Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. PMID: 29152076 Ref: Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. PMID: 29156578 Ref: Isolation of circulating tumor cells from pancreatic cancer by automated filtration. PMID: 29156783 Ref: Sphingomyelin metabolism is a regulator of KRAS function. PMID: 29158292 Ref: Challenges in Ras therapeutics in pancreatic cancer. PMID: 29170065 Ref: Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer. PMID: 29190947 Ref: Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. PMID: 29203670 Ref: Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. PMID: 29212165 Ref: Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. PMID: 29228654 Ref: EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis. PMID: 29245923 Ref: Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice. PMID: 29255459 Ref: Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. PMID: 29282264 Ref: Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. PMID: 29390348 |
Ref: Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. PMID: 27646934 Ref: IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. PMID: 27797936 Ref: Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. PMID: 27936345 Ref: Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. PMID: 28077438 Ref: c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis. PMID: 28159836 Ref: Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. PMID: 28715967 Ref: CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A. PMID: 28892048 Ref: RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. PMID: 29059158 Ref: SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. PMID: 29059173 Ref: Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. PMID: 29103024 Ref: Ultrasensitive MRI detection of spontaneous pancreatic tumors with nanocage-based targeted contrast agent. PMID: 29107217 Ref: Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. PMID: 29151594 Ref: Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. PMID: 29222037 Ref: KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. PMID: 29229669 Ref: Cilia loss sensitizes cells to transformation by activating the mevalonate pathway. PMID: 29237705 Ref: JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. PMID: 29248440 Ref: Kruppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice. PMID: 29248441 Ref: beta2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. PMID: 29249692 Ref: Detection of K-ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study. PMID: 29250161 Ref: NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. PMID: 29253566 Ref: Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. PMID: 29259015 Ref: Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. PMID: 29279356 Ref: Investigating the role of transcription factors of pancreas development in pancreatic cancer. PMID: 29289465 Ref: Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. PMID: 29290766 Ref: In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. PMID: 29301749 Ref: Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. PMID: 29303405 Ref: Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool? PMID: 29303908 Ref: KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. PMID: 29315556 Ref: Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. PMID: 29320425 Ref: Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. PMID: 29337182 Ref: Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. PMID: 29349096 Ref: KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. PMID: 29360815 Ref: Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. PMID: 29364867 Ref: Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. PMID: 29367463 Ref: Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury. PMID: 29367759 Ref: Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. PMID: 29371474 Ref: Role of metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) in pancreatic cancer. PMID: 29389953 Ref: Pancreatic cancer: KRAS dosage key in PDAC. PMID: 29410532 Ref: KRAS(G12D) Gene Dosage Drives Pancreatic Tumor Evolution and Progression. PMID: 29420182 Ref: Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer. PMID: 29433879 Ref: Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. PMID: 29452147 Ref: Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. PMID: 29464045 Ref: Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer. PMID: 29467941 Ref: Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. PMID: 29486633 Ref: Zeb1 in Stromal Myofibroblasts Promotes Kras-Driven Development of Pancreatic Cancer. PMID: 29490942 Ref: Intraductal Tubulopapillary Neoplasm of the Pancreas: An Overview. PMID: 29494224 Ref: The advanced glycation end-product N() -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. PMID: 29533466 Ref: Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids. PMID: 29543440 Ref: A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. PMID: 29564165 Ref: The Role of Next-Generation Sequencing in the Cytologic Diagnosis of Pancreatic Lesions. PMID: 29565213 Ref: Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. PMID: 29596894 Ref: Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. PMID: 29604293 Ref: Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. PMID: 29615514 Ref: Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. PMID: 29628435 Ref: Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS. PMID: 29658583 Ref: RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. PMID: 29661277 Ref: Generation and testing of clinical-grade exosomes for pancreatic cancer. PMID: 29669940 Ref: Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. PMID: 29670173 Ref: Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening. PMID: 29673279 Ref: A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. PMID: 29683208 Ref: Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models. PMID: 29683461 Ref: Pancreatic HIF2alpha Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. PMID: 29693047 Ref: KRAS fluorescence in situ hybridisation testing for the detection and diagnosis of pancreatic adenocarcinoma. PMID: 29695486 Ref: The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. PMID: 29702208 Ref: Analysis of Kras gene from induced pancreatic cancer rats administered with Momordicacharantia and Ocimumbasilicum leaf extracts. PMID: 29736383 Ref: Satellite RNA Increases DNA Damage and Accelerates Tumor Formation in Mouse Models of Pancreatic Cancer. PMID: 29748382 Ref: Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. PMID: 29780561 Ref: Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism. PMID: 29791786 Ref: NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. PMID: 29802158 Ref: In vivo reprogramming drives Kras-induced cancer development. PMID: 29802314 Ref: KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. PMID: 29851957 Ref: Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. PMID: 29860982 Ref: Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. PMID: 29864419 Ref: Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. PMID: 29865155 Ref: A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. PMID: 29870774 Ref: Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. PMID: 29903803 Ref: NFkappaB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. PMID: 29909021 Ref: Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. PMID: 29920275 Ref: Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer. PMID: 29940591 Ref: Soluble stroma-related biomarkers of pancreatic cancer. PMID: 29941541 Ref: Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. PMID: 29941929 Ref: Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice. PMID: 29977235 Ref: The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines. PMID: 29998364 Ref: Expression of miRNA-143 in Pancreatic Cancer and Its Clinical Significance. PMID: 30004802 Ref: S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. PMID: 30009399 Ref: Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer. PMID: 30037904 Ref: Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer. PMID: 30041673 Ref: Medullary carcinoma of the pancreas radiologically followed up as a cystic lesion for 9 years: a case report and review of the literature. PMID: 30043132 Ref: Serotonin uptake is required for Rac1 activation in Kras-induced acinar-to-ductal metaplasia in the pancreas. PMID: 30058725 Ref: GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. PMID: 30061636 Ref: Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. PMID: 30065098 Ref: Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. PMID: 30072705 Ref: Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. PMID: 30083262 Ref: A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer. PMID: 30088781 Ref: PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. PMID: 30100261 Ref: Beyond Kras: MYC Rules in Pancreatic Cancer. PMID: 30105283 Ref: Intrapancreatic recurrence of intraductal tubulopapillary neoplasm (ITPN) 16 years after the initial surgery for noninvasive ITPN: a case report. PMID: 30116990 Ref: Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. PMID: 30128034 Ref: STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. PMID: 30135074 Ref: Overhang molecular beacons encapsulated in tethered cationic lipoplex nanoparticles for detection of single-point mutation in extracellular vesicle-associated RNAs. PMID: 30145409 Ref: Pancreatic Cancer Cell Fraction Estimation in a DNA Sample. PMID: 30149376 Ref: Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. PMID: 30154150 Ref: Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. PMID: 30167093 Ref: p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. PMID: 30197477 Ref: Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway. PMID: 30213082 Ref: PKCiota and YAP1 are crucial in promoting pancreatic tumorigenesis. PMID: 30214681 Ref: KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. PMID: 30217561 Ref: Establishment of a noncoding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing. PMID: 30221677 Ref: Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy. PMID: 30223034 Ref: Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis. PMID: 30227250 Ref: Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma. PMID: 30227407 Ref: A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. PMID: 30228208 Ref: Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. PMID: 30229909 Ref: Circulating Nucleic Acids Associate with Outcomes of Patients with Pancreatic Cancer. PMID: 30240661 Ref: The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. PMID: 30241369 Ref: Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. PMID: 30242282 Ref: Mitochondrial Quality Control Mediated by PINK1 and PRKN: Links to Iron Metabolism and Tumor Immunity. PMID: 30252570 Ref: Cyclooxygenase-2 Influences Response to Co-Targeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. PMID: 30254182 Ref: Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells. PMID: 30261145 Ref: Host IDO2 gene status influences tumor progression and radiotherapy response in KRAS-driven sporadic pancreatic cancers. PMID: 30266763 Ref: Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. PMID: 30271501 Ref: KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer. PMID: 30283732 Ref: Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. PMID: 30286473 Ref: Levels of the Autophagy Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. PMID: 30296435 Ref: Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. PMID: 30301865 Ref: Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras(G12D/+);Tp53(R172H/+) (KPC) mice, a genetically engineered model of pancreatic cancer. PMID: 30306263 Ref: MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells. PMID: 30306823 Ref: SWI/SNF component ARID1A restrains pancreatic neoplasia formation. PMID: 30315093 Ref: Functionalized MoS2 Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy. PMID: 30324083 Ref: A Scalable Method for Squalenoylation and Assembly of Multifunctional (64)Cu-Labeled Squalenoylated Gemcitabine Nanoparticles. PMID: 30324084 Ref: Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer. PMID: 30325112 Ref: Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. PMID: 30346475 Ref: Ubiquitin-independent, Proteasome-mediated targeted degradation of KRAS in pancreatic adenocarcinoma cells using an engineered ornithine decarboxylase/antizyme system. PMID: 30347501 Ref: EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. PMID: 30349952 Ref: PIN1 maintains redox balance via the c-Myc/NRF2 axis to counteract Kras-induced mitochondrial respiratory injury in pancreatic cancer cells. PMID: 30355620 Ref: Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. PMID: 30361898 Ref: Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry. PMID: 30371656 Ref: PKM2 is not required for pancreatic ductal adenocarcinoma. PMID: 30386596 |